Association Between Persistent Treatment of Alzheimer’s Dementia and Osteoporosis Using a Common Data Model
10.12779/dnd.2023.22.4.121
- Author:
Seonhwa HWANG
1
;
Yong Gwon SOUNG
;
Seong Uk KANG
;
Donghan YU
;
Haeran BAEK
;
Jae-Won JANG
Author Information
1. Kangwon National University School of Medicine, Chuncheon, Korea
- Publication Type:Original Article
- From:Dementia and Neurocognitive Disorders
2023;22(4):121-129
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:and Purpose: As it becomes an aging society, interest in senile diseases is increasing. Alzheimer’s dementia (AD) and osteoporosis are representative senile diseases.Various studies have reported that AD and osteoporosis share many risk factors that affect each other’s incidence. This aimed to determine if active medication treatment of AD could affect the development of osteoporosis.
Methods:The Health Insurance Review and Assessment Service provided data consisting of diagnosis, demographics, prescription drug, procedures, medical materials, and healthcare resources. In this study, data of all AD patients in South Korea who were registered under the national health insurance system were obtained. The cohort underwent conversion to an Observational Medical Outcomes Partnership–Common Data Model version 5 format.
Results:This study included 11,355 individuals in the good persistent group and an equal number of 11,355 individuals in the poor persistent group from the National Health Claims database for AD drug treatment. In primary analysis, the risk of osteoporosis was significantly higher in the poor persistence group than in the good persistence group (hazard ratio, 1.20 [95% confidence interval, 1.09–1.32]; p<0.001).
Conclusions:We found that the good persistence group treated with anti-dementia drugs for AD was associated with a significant lower risk of osteoporosis in this nationwide study. Further studies are needed to clarify the pathophysiological link in patients with two chronic diseases.
